Sources: Cassava Sciences faces US criminal probe tied to Alzheimer’s drug

Source: Reuters

“The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer’s drug, two people familiar with the inquiry said. … The company already was facing scrutiny from the U.S. Securities and Exchange Commission and investors after two physicians from outside Cassava last year made allegations of data manipulation and misrepresentation involving research underpinning the company’s Alzheimer’s drug, called simufilam. … Cassava has received more than $20 million from the U.S. National Institutes of Health to support developing simufilam. The NIH told Reuters it does not discuss potential cases of research misconduct related to grants but that officials ‘take research misconduct very seriously.'” (07/27/22)